The duration of the inhibition of thymidylate synthase in intact L1210 cells exposed to two different classes of quinazoline analogues.
Kimbell
R
R
Drug Development Section, Institute of Cancer Research, Sutton, Surrey, U.K.
Jackman
A L
AL
Boyle
F T
FT
Hardcastle
A
A
Aherne
W
W
D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D002455:Cell Division / Q000187:drug effects; D003856:Deoxyuracil Nucleotides / Q000378:metabolism; D004354:Drug Screening Assays, Antitumor; D005492:Folic Acid / Q000031:analogs & derivatives* / Q000633:toxicity; D005493:Folic Acid Antagonists / Q000633:toxicity*; D007939:Leukemia L1210 / Q000201:enzymology*; D051379:Mice; D011799:Quinazolines / Q000633:toxicity*; D013329:Structure-Activity Relationship; D013876:Thiophenes / Q000633:toxicity*; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors*; D013942:Thymine Nucleotides / Q000378:metabolism
D000970:Antineoplastic Agents; D003856:Deoxyuracil Nucleotides; D005493:Folic Acid Antagonists; D011799:Quinazolines; D013876:Thiophenes; D013942:Thymine Nucleotides; D005492:Folic Acid; C007267:2'-deoxyuridylic acid; D013940:Thymidylate Synthase; C068874:raltitrexed; C059966:ICI 198583; C024157:thymidine 5'-triphosphate